Hongfeng Gu

State Key Laboratory Of Natural Medicines
Nanjing, 210009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Design, synthesis, and biological evaluation of novel brain-penetrant PARP7 inhibitors for the treatment of ischemic stroke.

Design, synthesis, and biological evaluation of novel brain-penetrant PARP7 inhibitors for the treatment of ischemic stroke.

Journal: European journal of medicinal chemistry

Published: May 21, 2026

Discovery of Highly Potent Phthalazinone Derivatives as PARP14 Inhibitors: From Structure-Based Virtual Screening to In Vivo Pharmacodynamic Activity.

Discovery of Highly Potent Phthalazinone Derivatives as PARP14 Inhibitors: From Structure-Based Virtual Screening to In Vivo Pharmacodynamic Activity.

Journal: Journal of medicinal chemistry

Published: April 20, 2026

Identification of an Orally Bioavailable Quinoline-Based Small-Molecule Tumor Necrosis Factor α (TNF-α) Inhibitor Featuring a Spirocyclic Scaffold.

Identification of an Orally Bioavailable Quinoline-Based Small-Molecule Tumor Necrosis Factor α (TNF-α) Inhibitor Featuring a Spirocyclic Scaffold.

Journal: Journal of medicinal chemistry

Published: March 31, 2026

Correction to "Discovery of Hydroxamic Acid Ester Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer".

Correction to "Discovery of Hydroxamic Acid Ester Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer".

Journal: Journal of medicinal chemistry

Published: March 07, 2026

Discovery of Oxime Ether Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer.

Discovery of Oxime Ether Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer.

Journal: Journal of medicinal chemistry

Published: January 13, 2026

Discovery of PKMYT1 Inhibitors with a Novel Scaffold for the Treatment of Triple-Negative Breast Cancer.

Discovery of PKMYT1 Inhibitors with a Novel Scaffold for the Treatment of Triple-Negative Breast Cancer.

Journal: Journal of medicinal chemistry

Published: December 22, 2025

Discovery of Novel and Highly Potent Wee1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia.

Discovery of Novel and Highly Potent Wee1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia.

Journal: Journal of medicinal chemistry

Published: October 28, 2025

PARP7: an Emerging Therapeutic Target-Insights into Biological Functions and Advances in Small-Molecule Inhibitor Development.

PARP7: an Emerging Therapeutic Target-Insights into Biological Functions and Advances in Small-Molecule Inhibitor Development.

Journal: Journal of medicinal chemistry

Published: September 25, 2025

Discovery of Orally Potent Small-Molecule CD73 Inhibitor for Cancer Immunotherapy.

Discovery of Orally Potent Small-Molecule CD73 Inhibitor for Cancer Immunotherapy.

Journal: Journal of medicinal chemistry

Published: May 23, 2025

Discovery and Optimization of Potent and Highly Selective PARP14 Inhibitors for the Treatment of Atopic Dermatitis.

Discovery and Optimization of Potent and Highly Selective PARP14 Inhibitors for the Treatment of Atopic Dermatitis.

Journal: Journal of medicinal chemistry

Published: April 16, 2025

Discovery and Optimization of Novel Apo-IDO1 Inhibitors by a Pharmacophore-Based Structural Simplification Strategy.

Discovery and Optimization of Novel Apo-IDO1 Inhibitors by a Pharmacophore-Based Structural Simplification Strategy.

Journal: Journal of medicinal chemistry

Published: March 05, 2025

New TIPARP inhibitor rescues mitochondrial function and brain injury in ischemic stroke.

New TIPARP inhibitor rescues mitochondrial function and brain injury in ischemic stroke.

Journal: Pharmacological research

Published: July 23, 2024

Showing 1-12 of 17

Last Updated: 09/26/2026